Floatz logo

cb-839

Waldenstrom's Macroglobulinemia (WM)

Calithera Biosciences, IncPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Waldenstrom's Macroglobulinemia (WM) cohort.

Asset / SponsorPhaseRating
Telaglenastat
Calithera Biosciences, Inc
Phase 1CC
Pomalidomide
Calithera Biosciences, Inc
Phase 1CC
exs73565
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase 1CC

Same molecule, other indications

cb-839 is also rated in:

KRAS Gene MutationDormant
CCC
Indicative ·
52 / 100
View asset →
CRCDormant
CCC
Indicative ·
48 / 100
View asset →
Other B-cell NHL Subtypes, Including WMDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →